📰 Junshi Bioscience News
Page 8 - Junshi Bioscience News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Junshi Bioscience. Real-time updates on events, politics, business and more.
April 3, 2022
SHANGHAI, China, April 03, 2022 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences," HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated
April 3, 2022
SHANGHAI, China, April 03, 2022 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading...
March 31, 2022
-Tackling the COVID-19 pandemic challenge with multi-pronged strategies - Pipeline progressed and expanded substantially SHANGHAI, China, March 31, 2022 (GLOBE NEWSWIRE) -- Shanghai Junshi
January 10, 2022
Junshi Biosciences and Coherus plan to evaluate the toripalimab + JS006 combination in clinical trials in multiple tumor typesCombinations of PD-1 + TIGIT inhibitors have potential to expand... | January 10, 2022
January 10, 2022
Investegate announcements from Junshi Biosciences, Junshi Biosciences and Coherus Expand Immuno-Oncology Collaboration to Include TIGIT-Targeted Antibody
December 20, 2021
/PRNewswire/ -- The "Global TROP2 Antibody Market & Clinical Trials Insight 2026" report has been added to ResearchAndMarkets.coms offering. The global Trop2...
December 20, 2021
/PRNewswire/ -- The "Global TROP2 Antibody Market & Clinical Trials Insight 2026" report has been added to ResearchAndMarkets.coms offering. The global Trop2...
December 18, 2021
The NRDL, a compilation that has existed for two decades, is part of the Chinese government’s plan to make health care affordable and accessible under the country’s socialist principles. Formally adopted in 2017 as an annual list, it forms part of the “common prosperity” aspiration pledged by President Xi Jinping.
November 1, 2021
FDA has granted the toripalimab BLA Priority Review with a target action date of April 2022SHANGHAI, China and REDWOOD CITY, Calif., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd.
October 15, 2021
/PRNewswire/ -- The "Neuroendocrine Tumors - Global Drug Forecast and Market Analysis to 2030" report has been added to ResearchAndMarkets.coms offering. The...